SUPPORTING TABLES for:

**Mesothelin-targeted thorium-227 conjugate (MSLN-TTC): Preclinical evaluation of a new targeted alpha therapy in mesothelin-positive cancers**

Urs B Hagemann1, Christine Ellingsen2,Joachim Schuhmacher3, Alexander Kristian2, Anne Mobergslien2, Véronique Cruciani2, Katrine Wickstroem2, Christoph A Schatz1, Christoph Kneip1, Sven Golfier1, Roger Smeets2, Steinar Uran2, Hartwig Hennekes1, Jenny Karlsson2, Roger M Bjerke2, Olav B Ryan2, Dominik Mumberg1, Karl Ziegelbauer1 and Alan S Cuthbertson2

1Bayer AG, Berlin, Germany; 2Bayer AS, Oslo, Norway; 3Bayer AG, Wuppertal, Germany

**SUPPORTING TABLES**

**Supporting Table S1. Summary of *in vitro* cytotoxicity experiments.**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Cell line** | **Origin** | **Antibodies bound per cell** | **IC50 (kBq/mL)** | **IC50 ratio** **(Control/BAY 2287411)** |
| HT29‑MSLN | Colon | 242,413 | 0.005 | 188 |
| NCI‑H226-*luc* | Lung/mesothelioma | 183,411 | 0.14 | 16 |
| OVCAR-3 | Ovarian | 37,877 | 1.3 | 10 |
| EKVX | Lung | 17,114 | 0.9 | 8 |
| AsPC‑1 | Pancreas | 17,000 | 9.9 | 4 |
| Capan-2 | Pancreas | 18,000 | 1.4 | 2 |
| NCI‑H322 | Lung | 4,600 | 8.9 | 2 |
| BxPC‑3 | Pancreas | 4,200 | 7.1 | 1 |
| HCT‑116 | Colon | 3,400 | 6.7 | 1 |
| KATO III | Gastric | 7,800 | 4.8 | 1 |
| UWB1.289 | Ovarian | 683 | 17 | 1 |
| UWB1.289+BRCA1 | Ovarian | 338 | 32 | 1 |

**Supporting Table S2. Median survival times in NCI-H226-*luc* lung cancer model.**

|  |  |
| --- | --- |
| **Treatment group** | **Median survival time****(days)** |
| Vehicle | 46 |
| BAY 2473626 (500 kBq/kg) | 63 \*\*\* |
| BAY 2287409 (-) | 48 \* |
| BAY 2287411 (100 kBq/kg) | 76 \*\*\* |
| BAY 2287411 (250 kBq/kg) | 130 \*\*\* |
| BAY 2287411 (500 kBq/kg) | 130 \*\*\* |

Statistical analysis was performed using Cox proportional-hazards model and comparing treatment groups to vehicle group.

\*, p < 0.05; \*\*\*, p < 0.001.